Milner Therapeutics Institute and Cambridge Enterprise welcome Curie.Bio to Cambridge
Last week, we joined forces with Cambridge Enterprise to welcome Curie.Bio to Cambridge – a venture capital firm that helps founders discover and develop important new medicines. We began the day by welcoming Curie.Bio leadership at the Milner Therapeutics Institute...
Immutrin raises £65 million in Series A funding to advance amyloidosis therapy
We’re delighted that Milner Institute Bio-incubator company Immutrin has announced the successful close of a £65 million ($87 million) Series A financing round to develop a next-generation antibody therapy for ATTR amyloidosis. This funding will enable Immutrin to...
Milner Institute to showcase collaboration and innovation at BioTrinity 2026
We’re delighted to announce that the Milner Therapeutics Institute will play an active role at BioTrinity 2026 next month, with both a dedicated showcase session and participation in a key panel discussion focused on collaboration in life sciences. BioTrinity...
Flagship–Cambridge partnership marks one year of therapeutic innovation and collaboration
In 2025, the Milner Therapeutics Institute, together with Cambridge University Health Partners, announced a collaboration with Flagship Pioneering – a scientific innovation engine for transformative platforms and products in human health, sustainability, and beyond....
Milner Institute hosts Cambridge–Oxford BioVenture Showcase, spotlighting high-potential biotech startups
On 22 January, we were delighted to host the Cambridge–Oxford BioVenture Showcase, bringing together innovators, early‑stage founders, researchers, investors, and industry partners from the Cambridge-Oxford corridor. The showcase created a dynamic forum for...
Milner Therapeutics Institute kickstarts 2026 with business-to-business event for affiliates
Last week, the Milner Institute welcomed more than 45 of its affiliated companies to a business-to-business networking event on the Cambridge Biomedical Campus. The event brought together start-ups from the Milner Bio-incubator and beyond, biotech, services and CRO...
Cathy Tralau-Stewart discusses strengthening UK therapeutic translation in Drug Discovery World
We’re delighted that our Executive Director, Professor Cathy Tralau-Stewart, has continued her thought leadership work with Drug Discovery World, with a timely article on “The role of universities and industry in driving translation of therapeutics: the need for a new...
Functional Genomics Screening Laboratory wins OBN Award for Most Impactful Industry Collaboration
We are thrilled to announce that the Functional Genomics Screening Laboratory (FGSL) has been awarded an OBN Award in the Most Impactful Industry Collaboration category. This recognises the pioneering work taking place in the FGSL — a collaboration between the Milner...